General Transcription Factor IIE Subunit 1 (GTF2E1), also known as TFIIE-alpha, is a critical component of the eukaryotic transcription pre-initiation complex (PIC). By recruiting and regulating TFIIH, GTF2E1 plays a pivotal role in transcription initiation, promoter escape, and DNA repair. Emerging research highlights GTF2E1 as a key driver of transcriptional addiction in multiple cancers, including hepatocellular carcinoma (HCC) and breast cancer, making it an attractive target for novel small-molecule protein-protein interaction (PPI) inhibitors and transcription-targeted therapies.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GTF2E1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GTF2E1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View GTF2E1 Products |
| Gene Delivery | GTF2E1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View GTF2E1 Products |
| Benchmark Ab | Anti-GTF2E1 Recombinant Antibody Recombinant positive control. |
View GTF2E1 Products |
| Validator | GTF2E1 siRNA Set For knockdown verification. |
View GTF2E1 Products |
| Related Target A | GTF2E2 TFIIE beta subunit; forms the functional heterotetramer with GTF2E1. |
View GTF2E2 Products |
| Related Target B | ERCC3 TFIIH subunit (XPB helicase); directly binds GTF2E1 to initiate transcription. |
View ERCC3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting functional transcription complexes in vitro | High-purity (>95%) recombinant GTF2E1 and TFIIE-beta (GTF2E2) proteins available for stoichiometry-controlled assembly. |
| Subfamily and subunit cross-reactivity screening | Homolog and partner panels (GTF2E1, GTF2E2, TFIIH subunits) strictly verified by mass spectrometry. |
| Lack of reliable positive assay controls | Clinical-grade benchmark antibodies and sequence-verified positive controls included. |
| Off-target effects and false positives in cellular assays | Validated siRNA sets included for target-specific knockdown and phenotypic rescue validation. |
Live GTF2E1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of general transcription machinery is undergoing a paradigm shift. While historical approaches were limited by systemic toxicity, modern drug discovery focuses on selective disruption of transcription factor protein-protein interactions (PPIs) in transcriptionally addicted cancers. GTF2E1 lies at the nexus of this strategy, as its interaction with TFIIH (ERCC3) is highly sensitized in rapidly proliferating tumor cells. Future clinical developments are poised to leverage small-molecule inhibitors and PROTAC degraders to selectively disrupt these complexes, sparing healthy tissue through precise therapeutic windows.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Oncology Biotechs | Hepatocellular Carcinoma, Triple-Negative Breast Cancer | High-throughput screening assays (TR-FRET/AlphaLISA) requiring high-purity, natively folded GTF2E1 and ERCC3 proteins. |
| PROTAC / Targeted Degraders | Targeted Protein Degradation Pioneers | Hematological Malignancies, Solid Tumors | Degradation kinetics assays requiring stable GTF2E1 overexpression via Lentivirus and target validation via siRNA knockdown. |
| Combination Therapies (w/ CDK7/9 inhibitors) | Translational Research Laboratories | Refractory and Drug-Resistant Cancers | Synergy validation panels using high-quality recombinant transcription factors to evaluate complex assembly disruption. |